Oxygen Containing Reactant Patents (Class 530/410)
  • Publication number: 20150024430
    Abstract: The disclosure relates to milk protein nanoparticles produced according to a polymerization method in which at least one protein, which is obtained from milk and which can be thermally plasticized, is plasticized using a plasticizing agent, such as for example, water or glycerol at temperatures between room temperature and 140° C., subjected to mechanical stress and subsequently retreated, for example, in the top down or bottom up method to form nanoparticles.
    Type: Application
    Filed: November 12, 2012
    Publication date: January 22, 2015
    Inventor: Anke Domaske
  • Publication number: 20140378670
    Abstract: The invention relates to the field of covalently attaching proteins to a substrate, particularly to methods of immobilizing proteins by posttranslationally modifying a cysteine residue of said protein through the addition of functional groups. The invention also relates to biological molecules used in such techniques, including proteins, and detection methods and kits that utilize such immobilized proteins, such as a microdevice or “protein chip”, a high-throughput screening device, and for the microscopy of proteins on a surface.
    Type: Application
    Filed: December 23, 2013
    Publication date: December 25, 2014
    Inventors: Charles Dale Poulter, Guillermo Roberto Labadi, Cecile Gauchet, Rochelle Frances Hawkins Bohaty
  • Patent number: 8911776
    Abstract: The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: December 16, 2014
    Inventor: Claresa Levetan
  • Publication number: 20140329290
    Abstract: The present invention allows formation of covalent bonds in a bioactive compound having at least one amino group so as to efficiently provide the compound modified with PEG. The present invention thus provides a functionalized polyethylene glycol having a structure that allows reaction of two aldehyde groups with one amino group to form two covalent bonds.
    Type: Application
    Filed: December 13, 2012
    Publication date: November 6, 2014
    Inventors: Yukio Nagasaki, Yutaka Ikeda, Hiromichi Kawasaki, Jinya Katamachi
  • Patent number: 8865188
    Abstract: Provided herein are methods and compositions for controlling assembly of modified viral core proteins, for example, into a viral capsid or a nanocage. In some embodiments, the disclosed modified viral core proteins comprise at least one mutation or modification that can substantially prevent assembly of the viral core proteins until assembly is desired. In some embodiments, assembly of the viral core proteins may be triggered, for example, by contacting the viral core proteins with a reducing agent and/or by reducing the concentration of a denaturant. The viral core proteins may self-assemble to form a viral capsid or nanocage.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: October 21, 2014
    Assignee: Biomed Realty, L.P.
    Inventors: Miguel de los Rios, Stephanie de los Rios, Jacek Ostrowski, Kenneth J. Oh, Ilan Zipkin
  • Publication number: 20140309175
    Abstract: Polymer conjugates containing a C1-inhibitor having at least one substantially non-antigenic polymer covalently attached to the C1-inhibitor via thiol group of the C1 inhibitor is provided. In the polymer conjugates of the present invention, the substantially non-antigenic polymer is attached to either free thiol from a cysteine of thiol generated from disulfide bonds in C1 inhibitor. Alternatively, the substantially non-antigenic polymer is attached to one of more thiols in C1 inhibitor via bifunctional spacer. In addition, methods of making the conjugates as well as methods of treatment using the conjugate of the present invention are also provided.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 16, 2014
    Inventors: Hong Zhao, Karen Yang
  • Patent number: 8859294
    Abstract: The object of the present invention is to provide a method for immobilizing the SpA protein on the surface of a substrate with high density without causing dimerization. The following method solves the object. That is, the method for binding a protein to a surface of a substrate, comprising steps (A) to (B): step (A) of preparing said protein to the surface, step (B) of supplying said protein to the surface, wherein said protein consists of a Protein A or at least one domain of A to E of said Protein A, and said protein comprises C-terminal modified amino acid sequence represented by SEQ ID:1(SFNRSEC).
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: October 14, 2014
    Assignee: Panasonic Corporation
    Inventors: Jin Muraoka, Takachika Azuma, Akikazu Murakami
  • Publication number: 20140296181
    Abstract: Described herein, at least in part, are methods of modulating oncogenic fusion proteins.
    Type: Application
    Filed: April 9, 2012
    Publication date: October 2, 2014
    Applicant: Coferon, Inc.
    Inventors: Lee Daniel Arnold, Kenneth W. Foreman
  • Publication number: 20140294877
    Abstract: The present invention is directed to an inventive polymeric carrier molecule according to generic formula (I) and variations thereof, which allows for efficient transfection of nucleic acids into cells in vivo and in vitro, a polymeric carrier cargo complex formed by a nucleic acid and the inventive polymeric carrier molecule, but also to methods of preparation of this inventive polymeric carrier molecule and of the inventive polymeric carrier cargo complex. The present invention also provides methods of application and use of this inventive polymeric carrier molecule and the inventive polymeric carrier cargo complex as a medicament, for the treatment of various diseases, and in the preparation of a pharmaceutical composition for the treatment of such diseases.
    Type: Application
    Filed: March 4, 2014
    Publication date: October 2, 2014
    Applicant: CUREVAC GMBH
    Inventors: Patrick BAUMHOF, Thomas SCHLAKE
  • Patent number: 8809274
    Abstract: Disclosed is an adhesive hemostatic agent based on non-blood constituents including DOPA, able to strongly adhere to collagen fibers, and which comprises an antifibrinolytic agent in addition to an esterified atelocollagen which is non-immunogenic and may become positively charged thereon such that the adhesive hemostatic agent has no possibility of mediating particular diseases or viral infections (HIV, HCV, HBV, CMV, etc), unlike conventional agents comprising blood constituents, and readily binds to negatively charged platelets at high adhesive strength, thus inducing quick blood coagulation. Also, provided is a method for preparing the same.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: August 19, 2014
    Assignees: Dalim Biotech Co., Ltd., Industry-Academic Cooperation Foundation, Yongsei-University
    Inventor: Hwal Suh
  • Patent number: 8809453
    Abstract: The present invention is directed to branched reactive water-soluble polymers comprising at least two polymer arms, such as poly(ethylene glycol), attached to a central aliphatic hydrocarbon core molecule through heteroatom linkages. The branched polymers bear at least one functional group for reacting with a biologically active agent to form a biologically active conjugate. The functional group of the branched polymer can be directly attached to the aliphatic hydrocarbon core or via an intervening linkage, such as a heteroatom, -alkylene-, —O-alkylene-O—, -alkylene-O-alkylene-, -aryl-O—, —O-aryl-, (—O-alkylene-)m, or (-alkylene-O—)m linkage, wherein m is 1-10.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: August 19, 2014
    Assignee: Nektar Therapeutics
    Inventors: Michael David Bentley, Xuan Zhao, Xiaoming Shen, William Dudley Battle, III
  • Publication number: 20140220633
    Abstract: The current invention reports a method for the purification of a not-glycosylated, heterologous polypeptide, which has been recombinantly produced in a prokaryotic cell, wherein the method comprises three chromatography steps of which the first chromatography step selected from i) hydrophobic charge induction chromatography, or ii) hydrophobic interaction chromatography, or iii) affinity chromatography, or iv) ion exchange chromatography, the second chromatography step is selected from i) anion exchange chromatography, or ii) cation exchange chromatography, or iii) hydroxylapatite chromatography, or iv) hydrophobic interaction chromatography, and the a third chromatography step is selected from i) hydrophobic charge induction chromatography, or ii) anion exchange chromatography, or iii) cation exchange chromatography, or iv) hydrophobic interaction chromatography, whereby the first chromatography step is an affinity chromatography in case of polypeptides capable of interacting with metal ligands, the second c
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Roberto Falkenstein, Birgit Weydanz, Nicole Fuehrler, Claudia Giessel, Sybille Gabel, Adelbert Grossmann, Friederike Hesse, Marc Pompiati, Andreas Schaubmar, Brigitte Kraemer
  • Patent number: 8791092
    Abstract: This invention provides novel compositions to inhibit the aggregation of amyloid proteins. In various embodiments the compositions comprise a molecular tweezers that binds lysine and/or arginine and thereby inhibits the aggregation of amyloidogenic proteins.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: July 29, 2014
    Assignees: The Regents of the University of California, The United States of America as represented by the Department of Veterans Affairs, Massachusetts Institute of Technology, Universitat Duisburg-Essen
    Inventors: Gal Bitan, Akila Shanmugam, Aleksey Lomakin, Thomas Schrader, Frank Gerrit Klarner, Peter Talbiersky, Jolanta Polkowska, Frank Bastkowski, Sharmistha Sinha, Sally Frautschy
  • Patent number: 8785598
    Abstract: Provided are a coenzyme Q10 nanoparticle, a method of preparing the same and a composition having the nanoparticle. According to the present invention, Coenzyme Q10 may be dissolved in only a water-miscible organic solvent, and easily made into a nano-sized particle and solubilized under a low energy condition, for example, by simple stirring. The coenzyme Q10 may be dispersion-stabilized by an amino acid or protein. The coenzyme Q10 is formed in a nano-sized particle and solubilized, an absorption rate may be increased and simultaneously deliver the amino acid and protein with the nanoparticle. Thus, the coenzyme Q10 nanoparticle can be effectively used in food, cosmetics and medicine.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: July 22, 2014
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Bong Hyun Chung, Jung Hyun Han
  • Patent number: 8742013
    Abstract: The present disclosure provides polymer compounds binding with lipoamide produced by the reaction of the primary amine group of lipoamide with the carboxy group of polysaccharide compounds such as chondroitin sulfates, carboxymethyl celluloses, or hyaluronic acids; functional compounds such as peptides, proteins, growth factors; or drugs; or biocompatible polymers such as poly(ethylene oxide), poly(vinyl alcohol), or poly(vinyl pyrrolidone). The present disclosure also provides their synthesis methods, products of hydrogels and films using the same as and methods for manufacturing the products.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: June 3, 2014
    Assignee: Seoul National University of Technology Center for Industrial Collaboration
    Inventors: Insup Noh, Seongyeun Jo, Doyeon Kim, Junghoon Woo
  • Publication number: 20140120154
    Abstract: The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue.
    Type: Application
    Filed: October 26, 2012
    Publication date: May 1, 2014
    Inventor: Claresa Levetan
  • Publication number: 20140056966
    Abstract: The present invention provides an anti-tumor or anti-angiogenesis medicament, the combination or kit containing the medicament, and the method for producing the same. The anti-tumor or anti-angiogenesis medicament contains a conjugate comprising a modifying agent and the angiostatin or its fragments, wherein the conjugate exhibits prolonged in vivo half-life as compared to an unmodified angiostatin or its fragments. The modifying agent is selected from the group consisting of macromolecular polymers, protein molecules or fragments thereof, peptides, small molecules, or chemical substances of any other forms.
    Type: Application
    Filed: June 5, 2012
    Publication date: February 27, 2014
    Applicant: PROTGEN LTD.
    Inventors: Yongzhang LUO, Guodong Chang, Shuling Yang, Lei Gao, Yan Fu
  • Publication number: 20140054163
    Abstract: Methods for labeling or modifying cysteine residues in proteins and/or enzymes are disclosed. The methods include the reaction of an o-naphthoquinone methide with a thiol group of a cysteine residue of a protein or enzyme, which can be reversible in preferred embodiments. The o-naphthoquinone methide can conveniently be generated by irradiation of a precursor compound, preferably in an aqueous solution, suspension, or dispersion.
    Type: Application
    Filed: February 20, 2013
    Publication date: February 27, 2014
    Applicant: University of Georgia Research Foundation, Inc.
    Inventors: VLADIMIR V. POPIK, GEERT-JAN BOONS, JUN GUO, SELVANATHAN ARUMUGAM, EMMANUEL NEKONGO, NANNAN LIN
  • Publication number: 20140039167
    Abstract: The invention conjugates that can be prepared by contacting a polymer comprising an acetal or ketal branching point with a pharmacologically active agent under conditions suitable to form a covalent attachment between the polymer and the pharmacologically active agent.
    Type: Application
    Filed: October 3, 2013
    Publication date: February 6, 2014
    Applicant: Nectar Therapeutics
    Inventors: Samuel P. McManus, Antoni Kozlowski
  • Publication number: 20130344590
    Abstract: An object of the present invention is to provide, as a method for immobilizing a protein molecule, protein immobilization method and means in which orientation of a molecule to be immobilized can be controlled, the molecule can be stably immobilized without a complicated process and a chemical group used for immobilization does not affect the activity and the function of the protein. Specifically, the present invention relates to a method for immobilizing a molecule including the steps of forming a labeled molecule by attaching a label peptide sequence comprising a hydroxyl group-containing amino acid to a molecule; and bringing a molecule having a phenylboronic acid group into contact with the labeled molecule, to capture the labeled molecule by the molecule having a phenylboronic acid group.
    Type: Application
    Filed: January 30, 2012
    Publication date: December 26, 2013
    Inventors: Tomohiro Konno, Kazuhiko Ishihara, Hirokazu Nishida
  • Publication number: 20130337536
    Abstract: The present disclosure is directed to a reactive ester agent capable of conjugating a reporter molecule to a carrier molecule or solid support. The reactive ester agent has the general formula: wherein the variables are described throughout the application.
    Type: Application
    Filed: August 21, 2013
    Publication date: December 19, 2013
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Evan Antoulinakis, Kyle Gee, Aleksey Rukavishnikov
  • Patent number: 8604127
    Abstract: The present invention relates to a conjugate of a protein or peptide with a polyethylene glycol derivative having catechol, wherein the protein or peptide is mono-PEGylated at the N-terminal with the polyethylene glycol derivative, and to a preparation method thereof. According to the invention, the catechol-PEG derivative can be site-specifically conjugated with the N-terminal amine group of a protein or peptide, so that a homogeneous polyethylene glycol-protein or -peptide conjugate can be obtained in high yield. Unlike a prior art conjugate, the conjugate obtained according to the invention allows the decrease in the activity of the protein to be minimized without chemically modifying the protein, and thus the conjugate has an excellent pharmacological effect. Also, because the conjugate is homogeneous, the process for preparing the conjugate can be simplified. Moreover, the conjugate has uniform biological efficacy in vivo and shows strong resistance to hydrolysis and thus a long in vivo duration time.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: December 10, 2013
    Assignees: Korea Advanced Institute of Science and Technology, Inno Therapy Inc.
    Inventors: Haeshin Lee, Hyukjin Lee, In Taek Song, Moon Sue Lee
  • Publication number: 20130324465
    Abstract: The invention provides compositions and methods for treating a disease or disorder associated with vascular endothelial growth factor (VEGF). Specifically, the invention relates to an oligomerized VEGF binding domain to provide VEGF antagonism, and thereby treat diseases associated thereof.
    Type: Application
    Filed: August 5, 2011
    Publication date: December 5, 2013
    Applicant: Genzyem Corporation
    Inventors: James Stefano, Clark Pan, Huawei Qiu, Michael O'Callaghan, Gloria Matthews
  • Publication number: 20130324701
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Application
    Filed: May 29, 2013
    Publication date: December 5, 2013
    Applicant: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Lewis T. WILLIAMS, Elizabeth BOSCH, Stephen K. DOBERSTEIN, Kevin HESTIR, Diane HOLLENBAUGH, Ernestine LEE, Minmin QIN QIN, Ali SADRA, Justin WONG, Ge WU, Hongbing ZHANG ZHANG
  • Patent number: 8575282
    Abstract: A modified compound that has at least one further functional group, in particular a bio- or macromolecule, comprising at least one x-fold (x?1) chemoselectively incorporated phosphoramidate group of general formula (I), NPO(OR1)(OR1?), and/or at least one x-fold (x?1) chemoselectively incorporated phosphonamide group of general formula (Ia), NPO(R1)(OR1?). R1 and R1? is selected from the group containing glycerol, polyglycerol, PEG polymers of the general empirical formula C2nH4n+2On+1 with n?1, Cn-alkyl chains with n?1; functionalized Cn-alkyl chains with n?1, aryls, heteroaryl, silyl, lipids, fluorophores, saccharides, peptides, crown ethers, or a linker, which links the aforementioned groups. R1 and R1? can be identical to or different from one another.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: November 5, 2013
    Assignee: Freie Universitaet Berlin
    Inventors: Christian Hackenberger, Giuseppe Del Signore, Remigiusz Serwa, Ina Wilkening, Robert Vallee
  • Publication number: 20130281357
    Abstract: Anti-angiogenic agents or polypeptides comprising an amino acid segment substantially similar to domain one of CD2 wherein the polypeptide has a ?-sheet formed by two segments. Methods of using such agents and polypeptide are also included.
    Type: Application
    Filed: July 13, 2011
    Publication date: October 24, 2013
    Applicant: Georgia State University Research Foundation
    Inventors: Zhi-Ren Liu, Jenny J. Yang, Yin Lu
  • Publication number: 20130274322
    Abstract: A new process for the manufacture of iodinated xanthenes in high purity includes a cyclization step followed by an iodination step. No extraction, chromatographic or solvent concentration steps are required, and the intermediate as well as final compounds are isolated via filtration or similar means. The process requires a single organic solvent, and the steps are completed at temperatures below 100° C. The exclusion of chloride ions, of chloride free-radicals, hypochlorite ions, or hypochlorous acid as reagents or from reagents that may generate these species in situ in the presence of oxidants, prevents undesirable impurity formation. Several new compounds have been conceived and isolated using these methods. These new compounds are also formed into new medicaments.
    Type: Application
    Filed: June 12, 2013
    Publication date: October 17, 2013
    Inventors: Jamie Singer, Eric A. Wachter, Timothy Scott, Marlon Lutz, Kevin Babiak
  • Publication number: 20130237474
    Abstract: Modified biosynthetic polypeptide fusion inhibitors, methods for manufacturing, and uses thereof are provided.
    Type: Application
    Filed: November 13, 2012
    Publication date: September 12, 2013
    Applicant: AMBRX, INC.
    Inventors: Roberto Mariani, Bruce E. Kimmel
  • Patent number: 8530626
    Abstract: Methods to produce keratin elastomer, involving: (A)(1) reacting a diisocyanate with a blocking agent to form a diisocyanate with one —NCO group blocked by the blocking agent and one —NCO group unblocked, (2) reacting the diisocyanate with one —NCO group blocked by the blocking agent and one —NCO group unblocked with keratin at about 100° to about 120° C. to form keratin urethane with —NCO group functionality (i.e., with one —NCO group unblocked), (3) optionally reacting the keratin urethane with —NCO group functionality with a compound capable of reacting with the —NCO group; (B) reacting a diisocyanate with keratin to form keratin elastomer; or (C) reacting a monoisocyanate with keratin to form keratin elastomer.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: September 10, 2013
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventor: Jeanette M. Cardamone
  • Publication number: 20130216539
    Abstract: The present invention includes methods of generating derivatives of a protein, as well as methods of treating a subject with the derivatized proteins. More particularly, the present invention includes methods of generating derivatives of HSP 70 proteins and methods of treating a subject with the derivatized HSP 70 proteins.
    Type: Application
    Filed: February 15, 2013
    Publication date: August 22, 2013
    Applicant: ALS Biopharma, LLC
    Inventor: ALS Biopharma, LLC
  • Publication number: 20130196928
    Abstract: This application relates to ABx toxin mutants and libraries of said mutant proteins, in which a peptide insert is introduced into the protease-sensitive loop of the A-chain sequence to alter the type of cells to which toxic species are delivered. Said libraries are used in the development of therapeutics targeted against specific cell types.
    Type: Application
    Filed: January 11, 2013
    Publication date: August 1, 2013
    Applicant: MOLECULAR TEMPLATES, INC.
    Inventor: Molecular Templates, Inc.
  • Publication number: 20130190478
    Abstract: The current invention reports a method for the purification of a non-glycosylated, heterologous polypeptide, which has been recombinantly produced in a prokaryotic cell, wherein the method comprises three chromatography steps of which the first chromatography step selected from i) hydrophobic charge induction chromatography, or ii) hydrophobic interaction chromatography, or iii) affinity chromatography, or iv) ion exchange chromatography, the second chromatography step is selected from i) anion exchange chromatography, or ii) cation exchange chromatography, or iii) hydroxylapatite chromatography, or iv) hydrophobic interaction chromatography, and the a third chromatography step is selected from i) hydrophobic charge induction chromatography, or ii) anion exchange chromatography, or iii) cation exchange chromatography, or iv) hydrophobic interaction chromatography, whereby the first chromatography step is an affinity chromatography in case of polypeptides capable of interacting with metal ligands, the second c
    Type: Application
    Filed: September 21, 2012
    Publication date: July 25, 2013
    Inventor: Hoffmann-La Roche Inc.
  • Publication number: 20130183712
    Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with posttranslational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engine˜red mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.
    Type: Application
    Filed: February 22, 2013
    Publication date: July 18, 2013
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventor: California Institute of Technology
  • Publication number: 20130171715
    Abstract: Fluorescent phenyl xanthene dyes are described that comprise any fluorescein, rhodamine or rhodol comprising a particular C9 phenyl ring. One or both of the ortho groups on the lower C9 phenyl ring is ortho substituted with a group selected from alkyl, heteroalkyl, alkoxy, halo, haloalkyl, amino, mercapto, alkylthio, cyano, isocyano, cyanato, mercaptocyanato, nitroso, nitro, azido, sulfeno, sulfinyl, and sulfino. In one embodiment, halo and/or hydroxy groups are used. Optimal dyes contain a lower C9 phenyl ring in which both ortho groups are the same and the lower ring exhibits some form a symmetry relative to an imaginary axis running from the phenyl rings point of attachment to the remainder of the xanthene dye through a point para to the point of attachment. The phenyl xanthene dyes may be activated. Furthermore, the phenyl xanthene dyes may be conjugated to one or more substances including other dyes.
    Type: Application
    Filed: January 16, 2013
    Publication date: July 4, 2013
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventor: LIFE TECHNOLOGIES CORPORATION
  • Publication number: 20130165382
    Abstract: The present invention relates to the formation of conjugates (e.g., protein-protein dimers) using a-halo-acetophenones, benzylic halides, quinones, and related compounds as a conjugating system. The invention also features compositions that include the conjugates described herein, as well as uses of these conjugates in methods of medical treatment.
    Type: Application
    Filed: June 1, 2011
    Publication date: June 27, 2013
    Applicant: ADVANCED PROTEOME THERAPEUTICS INC.
    Inventors: Alexander Krantz, Peng Yu
  • Publication number: 20130165383
    Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided. In addition, therapeutic methods for using Apo-2 ligand variant polypeptides are provided.
    Type: Application
    Filed: April 6, 2012
    Publication date: June 27, 2013
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Sarah Hymowitz
  • Publication number: 20130156818
    Abstract: Provided herein are methods and compositions for controlling assembly of modified viral core proteins, for example, into a viral capsid or a nanocage. In some embodiments, the disclosed modified viral core proteins comprise at least one mutation or modification that can substantially prevent assembly of the viral core proteins until assembly is desired. In some embodiments, assembly of the viral core proteins may be triggered, for example, by contacting the viral core proteins with a reducing agent and/or by reducing the concentration of a denaturant. The viral core proteins may self-assemble to form a viral capsid or nanocage.
    Type: Application
    Filed: September 10, 2012
    Publication date: June 20, 2013
    Inventors: Miguel de los Rios, Stephanie de los Rios, Jacek Ostrowski, Kenneth J. Oh, Ilan Zipkin
  • Publication number: 20130157284
    Abstract: The invention relates to intracellular lipid binding proteins that bind retinoids and/or dye ligands and that are modified to transmit or emit light at a variety of different wavelengths.
    Type: Application
    Filed: March 23, 2011
    Publication date: June 20, 2013
    Applicant: Board of Trustees of Michigan State University
    Inventors: Babak Borhan, James Geiger, Wenjing Wang, Chrysoula Vasileiou, Kin Sing Lee, Tetyana Berbasova
  • Publication number: 20130149732
    Abstract: A method of labeling a sulfenic acid (—SOH) group of a cysteine residue in a protein; or peptide, comprises contacting said protein or peptide with a beta-ketoester to covalently couple said beta-ketoester to said cysteine residue and form a beta-ketoester-labeled cysteine residue in said protein or peptide.
    Type: Application
    Filed: August 24, 2012
    Publication date: June 13, 2013
    Inventors: Cristina M. Furdui, Allen W. Tsang, Jiang Qian
  • Patent number: 8450276
    Abstract: A method of improving the resistance of collagenous tissue to mechanical degradation in accordance with the present invention comprises the step of contacting at least a portion of a collagenous tissue with an effective amount of a crosslinking reagent. Methods and devices for enhancing the body's own efforts to stabilize discs in scoliotic spines by increasing collagen crosslinks. This stability enhancement is caused by reducing the bending hysteresis and increasing the bending stiffness of scoliotic spines, by injecting non-toxic crosslinking reagents into the convex side of discs involved in the scoliotic curve. Alternatively, contact between the tissue and the crosslinking reagent is effected by placement of a time-release delivery system directly into or onto the target tissue.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: May 28, 2013
    Assignee: Orthopeutics L.P.
    Inventor: Thomas P. Hedman
  • Patent number: 8449880
    Abstract: Disclosed herein is a composition and method for sample preparation of proteins for their size separation by electrophoresis, suitable for molecular-weight determination of proteins in the range between about 14,000 and 500,000. In an embodiment, proteins, particularly those exhibiting biased migration, are modified to change their intrinsic charge, or carbohydrate component to improve accuracy of their molecular weights as determined by electrophoretic size separation via their interaction with ionic surfactants. In a preferred embodiment, the proteins are carbamylated with potassium cyanate and their carbohydrate components are oxidized with sodium periodate.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: May 28, 2013
    Inventors: Vladislav Dolnik, William A. Gurske
  • Publication number: 20130115252
    Abstract: A method of preparing genipin-rich materials from the fruit of Genipa americana fruit for their use as a cross-linking agent and as a raw material to produce colors is disclosed. The genipin-rich materials can be used in a broad range of applications including personal care, cosmetics, dietary supplements, packaging, textiles, beverages, foodstuffs, drugs, and animal feeds.
    Type: Application
    Filed: November 7, 2012
    Publication date: May 9, 2013
    Applicant: Wild Flavors, Inc.
    Inventor: Wild Flavors, Inc.
  • Publication number: 20130109072
    Abstract: A support for enzyme immobilization is described, which is for immobilizing enzymes of various molecular sizes and also for, due to the modification of the surface silanol groups of porous silica particles, for immobilizing various kinds of enzymes, and enables the design of an immobilized enzyme, which exhibits an activity equivalent to that of the corresponding non-immobilized enzyme and withstands repeated use. A method for producing the support is also described. The support includes porous silica particles having an interparticle void structure therein, characterized in that the porous silica particles have a specific average particle size, a specific surface area, a specific pore volume, a specific pore size distribution and a specific porosity and have a substituent containing an organic group or an amino group on the surface thereof. An immobilized protein obtained by immobilizing a protein on the above support is also described.
    Type: Application
    Filed: June 8, 2011
    Publication date: May 2, 2013
    Applicants: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, JGC CORPORATION
    Inventors: Tatsuo Tsunoda, Takayuki Nara, Seigo Ono, Chisato Sekikawa, Fujio Mizukami, Shuzo Kojima, Naoki Tahara, Hideaki Togashi, Miki Egami
  • Publication number: 20130108578
    Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided.
    Type: Application
    Filed: May 17, 2012
    Publication date: May 2, 2013
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Stephanie Ho Lindstrom
  • Patent number: 8414880
    Abstract: Photosensitizer mixtures and method of treating cellulites by light illumination are presented. Photosensitizer is combined with cellular products, e.g. adipose cells, collagen, previously removed by liposuction. Concentrations used depend on treatment area, cellulite stage and whether cellulites are in depressed or elevated skin areas. The cosmetic treatment reduces/removes localized lipodystrophies, flaccidity, cellulite using localized laser, LED, etc emissions. Applied light energy destroys “fat” cells by a combination of chemical reactions primarily, and temperature, wherein cell walls break releasing cell fluid. Transmission devices guide radiation to the treatment site. One or more light sources like laser diodes or LEDs may be coupled into one or more optical fibers to increase the covered area and increase the amount of radiation in that area. Optical fibers can be introduced percutaneously or interstitially. Cell fluid in the treatment area is removed by a combination of techniques.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: April 9, 2013
    Assignee: Bioliter Pharme Marketing Ltd
    Inventors: Danilo Castro, Wolfgang Neuberger
  • Patent number: 8409814
    Abstract: The present invention relates to biosensors. In some embodiments, the biosensors are modified ligand binding molecules. In some embodiments, the modified ligand binding molecule is a phosphate binding protein (PBP). In some embodiments, the modified ligand binding molecules are labeled to be capable of RET, e.g., comprising a donor and acceptor moiety. In some embodiments of the invention, there is a detectable change in RET (e.g., FRET) when the modified ligand binding molecule binds and/or releases the ligand (e.g., phosphate). The invention also provides related methods, reactions and assays.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: April 2, 2013
    Assignee: Life Technologies Corporation
    Inventors: Kurt Vogel, Rhonda Newman, Steven Riddle
  • Publication number: 20130079499
    Abstract: Disclosed are: an Fc binding protein having increased stability with respect to heat, acid, and/or alkalinity compared with the wild type; a method for producing same; and a method for specifically isolating protein containing an Fc binding protein binding site using said Fc binding protein as a ligand for affinity chromatography. An Fc binding protein was obtained having increased stability with respect to heat, acid, and/or alkalinity compared with the wild-type human Fc receptor by means of substituting at least one specific amino acid residue in the extracellular domain of the wild-type human Fc receptor with another amino acid residue. The Fc binding protein is useful as a ligand for affinity chromatography for example by immobilizing in a solid phase.
    Type: Application
    Filed: March 10, 2011
    Publication date: March 28, 2013
    Applicants: TOSOH CORPORATION, SAGAMI CHEMICAL RESEARCH INSTITUTE
    Inventors: Kouta Hatayama, Yoshiharu Asaoka, Toru Tanaka, Teruhiko Ide
  • Publication number: 20130053548
    Abstract: Protein A crystals and Protein A cross-linked protein crystals (CLPCs) are described. Methods of preparing and using are also disclosed.
    Type: Application
    Filed: September 13, 2010
    Publication date: February 28, 2013
    Inventors: Bhami Shenoy, Sibyl Baladi, Reena Patel, Margaret McGrath, Nazer Khalaf, Chanchal Randhawa
  • Publication number: 20130041135
    Abstract: Provided are a filler for affinity chromatography which has excellent alkali resistance, and a method for isolating immunoglobulin. The filler for affinity chromatography is a filler in which a protein represented by the following formula (1) is immobilized on a carrier. R—R2 ??(1) wherein R represents an amino acid sequence consisting of 4 to 300 amino acid residues containing a region consisting of 4 to 20 contiguous histidine residues; and R2 represents an amino acid sequence capable of binding to immunoglobulin, the amino acid sequence consisting of 50 to 500 amino acid residues containing Z domain of Protein A or a fragment thereof, or a variant thereof, provided that the R binds to C-terminus or N-terminus of the R2.
    Type: Application
    Filed: March 23, 2011
    Publication date: February 14, 2013
    Applicant: JSR CORPORATION
    Inventors: Kouji Tamori, Tetsuo Fukuta, Masaaki Miyaji, Yong Wang, Takayoshi Abe, Yusuke Okano, Masaki Momiyama, Takahiro Kawai
  • Publication number: 20130040362
    Abstract: The present invention is directed to a method for producing a biomolecule conjugate where the method is integrated into a single unit operation.
    Type: Application
    Filed: February 21, 2011
    Publication date: February 14, 2013
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Jens H. Vogel, Chi Shung Brian To, Carolina Lucia Bianco